 |
|
|
| |
IAS
22 to 26 July 2024
AIDS 2024, the 25th International AIDS Conference
|
| |
| |
- What is HIV-Associated Neurocognitive Disorder (HAND) & Its Symptoms -
(08/12/24)
-
The DoxyPEP Debate: To DoxyPEP or not to DoxyPEP? -
(08/26/24)
- Negative Perception of Self & Stigma & Depression associated with Worse Expectations of Aging in Brazil -
(08/26/24)
- Differences between integrase strand transfer
inhibitors on glucose tolerance: a role for mitochondrial stress -
(08/19/24)
-
New HIV Drug Development at IAS 2024 -
(08/19/24)
- Aging, Metabolics & Weight Studies at IAS 2024 -
(08/12/24)
- Switching to doravirine in the absence of genotypic resistance tests in people living with HIV virally suppressed on antiretroviral treatment at a London HIV clinic -
(08/06/24)
- Phase 1, open-label study to evaluate the drug interaction between MK-8527, an HIV-1 nucleoside reverse transcriptase translocation inhibitor, and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females -
(08/06/24)
- Population pharmacokinetics (POPPK) for thigh as
alternative Rilpivirine Long-Acting (RPV LA) injection site -
(08/06/24)
-
Cabotegravir/rilpivirine long-acting therapy
real world experience in a large clinical cohort of HIV patients -
(08/06/24)
-
CAB/RPV-LA in patients with history of failure and/or drug resistance mutations to NNRTIs or INSTIs: the experience of a French university hospital -
(08/06/24)
- Resistance Analyses During Treatment of Lenacapavir with Broadly Neutralizing Antibodies in People with HIV -
(08/06/24)
-
Assessment of Longitudinal Changes in Renal Function of HIV-1 Oral Pre-Exposure Prophylaxis Users Using Real-World Data in the United States -
(08/06/24)
- Assessment of Longitudinal Changes in Renal Function of HIV-1 Oral Pre-Exposure Prophylaxis Users Using Real-World Data in the United States -
(08/06/24)
- Experiences and Quality of Life with Long-Acting Lenacapavir from People with Multidrug-Resistant HIV-1 Enrolled in the Phase 2/3 CAPELLA Study -
(08/06/24)
-
Predicting Retention in Care Before and After the COVID-19 Pandemic Among People With HIV -
(08/06/24)
-
Long-acting oral PrEP is preferred to injections: findings from an online sample of American gay, bisexual, and other men who have sex with men -
(08/06/24)
-
Weight Gain and Health-Related Quality of Life in PWH on ART -
(08/06/24)
-
Lack of Understanding of Undetectable Equals Untransmittable (U=U) is High Among PLWH in US -
(08/06/24)
- Bone health in Malaysian women living with HIV: uncovering the pores in osteoporosis screening and management in a high-risk population -
(08/05/24)
- ART Use and HTLV-1 Tied to hrHPV Persistence in Kenyan Women With HIV - Mark Mascolini
(08/03/24)
- Changes in body mass index before and after starting dolutegravir and compared to protease inhibitors in children and adolescents living with HIV in Europe and Thailand -
(08/03/24)
- PAIRED - PAtIent Reported Experiences and perceiveD Benefit of Treatment With Dolutegravir/Lamivudine (DTG/3TC) - Qualitative Interviews: Diverse Group of People With HIV-1 (PWH) Reflect on Life and Health -
(08/03/24)
- Prenatal Dolutegravir-Based Regimen Use, and Pregnancy and Birth Outcomes: Data From The Antiretroviral Pregnancy Registry -
(08/03/24)
- Effectiveness and durability of dolutegravir/rilpivirine in older people with HIV from the Veterans Aging Cohort Study (VACS) -
(08/03/24)
- Adolescents and young adults with HIV using long-acting injectable cabotegravir/rilpivirine as a standard of care: outcomes of the observational cohort at 26 months -
(08/03/24)
- Increased incidence of emergent integrase drug resistance with cabotegravir versus dolutegravir in randomised switching trials -
(08/03/24)
- Time is of the essence: clinical frailty among a cohort of Indigenous peoples aging with HIV in Ontario, Canada -
(08/03/24)
- An assessment of clinical frailty and early aging among a cohort of people living with HIV in Ontario, Canada....41% prefrailty (age 44), 6% frailty (age 55): indicators of frailty & prefrailty; IDU history increased risk, previous AIDS increased risk -
(08/03/24)
- Geriatric syndromes and quality of life in older adults living with HIV in Brazil....50% Pre-frail, 6% frail....age 62, CD4 700+, 90% undetectable viral load....greater services needed ! -
(08/03/24)
- Early experiences with usage of injectable cabotegravir (CAB-LA) among Kenyan and Ugandan adults participating in the SEARCH Dynamic Choice HIV Prevention trial: a qualitative study....self & external stigma, convenience, feeling healthy -
(08/03/24)
- Pre-Exposure Prophylaxis product choice of participants in HPTN 083 -
(08/03/24)
- Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention: the HPTN 084-01 study -
(08/03/24)
- CAB-LA for PrEP Earns High Satisfaction Rates (90%) in Rural Kenya and Uganda - Mark Mascolini
(08/03/24)
-
Unruly Natural Killer Cells May Figure in
CVD Risk in HIV+ Adolescents -
Mark Mascolini (08/02/24)
- HCV incidence among MSM using HIV PrEP and MSM with HIV in a New York City Health Care System over 2 decades - (08/02/24)
- (Implants) Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort - (08/02/24)
- An assessment of clinical frailty and early aging among
a cohort of people living with HIV in Ontario, Canada - (08/01/24)
- Comprehensive geriatric assessment for people living with HIV and frailty: a feasibility randomized controlled trial - (08/01/24)
-
Perceptions on frailty and frailty screening of people living with HIV and their healthcare professionals in Ethiopia: a qualitative study - (08/01/24)
- Frailty and multimorbidity in mid-aged and older
adults living with HIV: a cross-sectional study in Zimbabwe - (08/01/24)
- Polypharmacy Contributes to Frailty & Falls - CHANGE-Rx: frailty, falls, polypharmacy, and inappropriate medication use in a Canadian cohort of people aged 65 and older living with HIV....53% of older PWH have frailty - (08/01/24)
- Hypertension management and risk of dementia in people with and without HIV infection - (08/01/24)
- Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort - (08/01/24)
- Dolutegravir with recycled nucleoside reverse transcriptase inhibitors maintains better viral suppression than protease inhibitor based antiretroviral therapy over 144 weeks: VISEND Trial - (08/01/24)
- Influencers and Decision-Making Factors for Choosing Injectable PrEP Among Men Who Have Sex With Men and Transgender Men in the United States - (08/01/24)
- Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) in the U.S currently using daily-oral PrEP - (08/01/24)
- Need for Improved HIV Testing Prior to and During Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injections in Routine Clinical Care in the United States: Low Rates of HIV Tesing - (08/01/24)
- Only 9% PrEP Use Among Transfeminine Persons: HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons with high likelihood of HIV in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST) - (08/01/24)
- "The simplest way to go:" A mixed methods analysis of why women who inject drugs selected long-acting injectable cabotegravir instead of daily oral PrEP.....95% of women initiated CAB Lai PrEP !!! - (07/31/24)
- Efficacy of dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the phase 3/3b GEMINI-1/-2, STAT, TANGO, and SALSA - (07/31/24)
- Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 - (07/31/24)
- Switching from a second-line ritonavir-boosted protease inhibitor (PI/r)-based regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): results of a randomized clinical trial - (07/31/24)
-
Extended efficacy and safety of dolutegravir and darunavir containing regimens at week 96 in the international randomised clinical trial: D2EFT
- (07/31/24)
- Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies - (07/31/24)
-
What drives Comorbidities in PWH Highlights From Aging Pre-Conference Talks, at AIDS 2024 - (07/31/24)
- Assessing Comorbid Conditions in HIV/AIDS Patients: Insights from the CHAO (Comorbidities of HIV/AIDS Outpatients) Study in Meru County, Kenya and Their Role in Shaping Integrated Health Care Approaches - (07/31/24)
-
Prevalence and associated factors of chronic kidney
disease in young people living with HIV in Uganda
- (07/31/24)
- Increased cardiovascular risk in perinatally HIV-acquired adolescents (PHIV) may linked to proinflammatory NK cells - (07/31/24)
- ViiV HEALTHCARE ANNOUNCES POSITIVE NEW DATA FOR APRETUDE USE DURING PREGNANCY AT AIDS 2024 - (07/30/24)
-
ViiV HEALTHCARE ANNOUNCES POSITIVE DATA DEMONSTRATING 2-DRUG REGIMEN DOVATO IS AS EFFECTIVE AS 3-DRUG REGIMEN BIKTARVY FOR MAINTENANCE THERAPY OF HIV-1 - (07/30/24)
- ViiV HEALTHCARE PREMIERES EARLY DATA SHOWING ANTIVIRAL ACTIVITY AGAINST INTEGRASE RESISTANCE FROM ITS INVESTIGATIONAL, THIRD-GENERATION INTEGRASE INHIBITOR - (07/30/24)
- Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies - (07/30/24)
- Switching to B/F/TAF in a Real-World Cohort of Older People
With HIV and a High Burden of Non-AIDS-Related Comorbidities - (07/30/24)
-
Fine Differences Among Five Anal Cancer Screening Strategies in HIV Group - Mark Mascolini (07/30/24)
- Preclinical Assessments of a Cabotegravir Prodrug
Predicting Human Dosing Durations of >6 Months - (07/30/24)
- Prevalence of high risk penile human papillomavirus in men who have sex with men (MSM) and transgender women (TGW) - (07/30/24)
- Pre-Clinical Profiles of HIV-1 Capsid Inhibitors
VH4004280 (VH-280) and VH4011499 (VH-499) - (07/30/24)
- GS-8588, A Novel Envelope-Targeting Bispecific T-Cell Engager for HIV Cure - (07/30/24)
- Injection Site Reactions with Subcutaneous Lenacapavir
Administration at Alternate Injection Sites - (07/30/24)
- Real-World Adherence of HIV-1 Oral Pre-Exposure Prophylaxis Regimens in the USA:
A Group-Based Trajectory Modeling Approach - (07/30/24)
-
Initial evaluation of injectable cabotegravir (CAB-LA) safety
during pregnancy in the HPTN 084 open-label extension - (07/30/24)
-
Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy - (07/30/24)
- Nonclinical Pharmacology Profile of GS-1720, a Novel, Highly Potent, Once-Weekly Oral HIV-1 Integrase Strand Transfer Inhibitor in Clinical Development - (07/29/24)
- Safety and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GS-4182, an Oral Prodrug of Lenacapavir, in Participants without HIV-1 - (07/29/24)
- Clinical Pharmacokinetics and Safety of Orally Administered VH4004280 (VH-280), a Novel HIV-1 Capsid Inhibitor, in Adults Without HIV - (07/29/24)
- Clinical Outcomes at Month 12 After Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND) - (07/29/24)
- Perspectives of People With HIV (PWH) 12 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) - (07/29/24)
- Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Cohort Study - (07/29/24)
- 12-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study Who Switched Off Suppressive Oral Daily ART - (07/29/24)
- Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile - (07/29/24)
- In vitro characterization of VH4524184 (VH-184, S-365598), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile - (07/29/24)
-
The next Berlin patient: sustained HIV remission surpassing five years without antiretroviral therapy after heterozygous CCR5 WT/Δ32 allogeneic hematopoietic stem cell transplantation - (07/29/24)
- Subcutaneous injections of cabotegravir + rilpivirine in virally suppressed adults with HIV-1: a substudy of the Phase 3 FLAIR study - (07/29/24)
- Long-acting cabotegravir (CAB) plus rilpivirine (RPV) in the first, virologically-suppressed adolescents with HIV-1 to receive an every 8-week, all-injectable regimen in a multicenter, multinational Study: IMPAACT 2017 week 48 outcomes - (07/29/24)
- CAB LA Plus RPV Every 2 Months Controls HIV in Adolescents - Mark Mascolini (07/29/24)
- Efficacy, safety and tolerability of switching to dolutegravir/lamivudine
in virologically suppressed adults living with HIV on
bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study - (07/29/24)
- Efficacy, safety and tolerability of switching to dolutegravir/lamivudine
in virologically suppressed adults living with HIV on
bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study - (07/29/24)
- Randomised placebo-controlled trial of high-dose vitamin D and low-dose calcium supplementation to improve bone density in adolescents with perinatally-acquired HIV in Southern Africa - (07/28/24)
- Neurocognitive trajectories among a young adult cohort from four
African countries: associations with HIV and food insecurity - (07/28/24)
- Increased biomarkers of cardiovascular disease in a long-term survivor cohort of young adults living with perinatal HIV with virologic non-suppression or metabolic syndrome - (07/28/24)
-
Vitamin D Plus Calcium Improves Bone Density in HIV Youth Who Start With Low Density - Mark Mascolini (07/28/24)
- Three CVD Markers High in 347 Young Adults With HIV in Thailand - Mark Mascolini (07/28/24)
-
Multimorbidity by sex at birth among ageing (65 years and older) persons with HIV (PWH) in the Southern United States (US) - (07/28/24)
- Doxycycline PrEP prevents STIs without affecting vaginal
bacterial flora in female sex workers in Tokyo - (07/28/24)
- Evaluation of long-acting cabotegravir (CAB-LA) pharmacokinetics during pregnancy: a sub-study analysis of the HPTN 084 open label extension study - (07/28/24)
- High Interest in LA PrEP Among MSM in Europe Survey - Intention to use long-acting PrEP among MSM in Europe -results from the PROTECT survey from Spain, Italy, Germany, France and the United Kingdom - (07/28/24)
- STI testing rates among PrEP users randomized to 3-monthly (standard of care) or 6-monthly monitoring within the EZI-PrEP trial, the Netherlands: preliminary results - no difference in STIs between 6 vs 3 months visits - (07/28/24)
- Knowledge, awareness, feasibility, and acceptability of long-acting Cabotegravir for HIV prevention: results from the SEARCH Dynamic Choice HIV prevention trial - (07/28/24)
- Centering Community Leadership with PURPOSE: Inclusion of Adolescents, Cisgender Women, and Pregnant and Lactating Individuals in a Phase 3 Clinical Trial Evaluating Lenacapavir and Emtricitabine/Tenofovir Alafenamide for PrEP - (07/28/24)
- Twice-Yearly Lenacapavir or Daily Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study - (07/28/24)
-
Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial - (07/28/24)
- Detailed modelling of viremia exposure does not independently predict cardiovascular disease in people with HIV - (07/28/24)
- Risk of major cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: retrospective cohort analyses using routine, de-identified data from South Africa - (07/28/24)
- Integrating non-communicable disease screening and treatment in antiretroviral clinics: insights from Malawi - (07/28/24)
- A pilot study assessing changes in cerebral function parameters in persons with insomnia switching integrase inhibitors - (07/28/24)
- DoxyPrEP Cuts STI Rate in FSW Without Fueling Other Infections - Mark Mascolini (07/27/24)
- A pilot, randomized controlled trial of doxycycline pre-exposure prophylaxis versus placebo for prevention of bacterial sexually transmitted infections in men who have sex with men living with HIV - (07/27/24)
-
Community-Based HCV Self-Testing Widens Testing Access in Big Vietnam Study - Mark Mascolini (07/27/24)
- Third-Generation Integrase Inhibitor Remains Active Against Resistant HIV in Lab - Mark Mascolini (07/27/24)
- Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral regimens at baseline - (07/27/24)
- Bictegravir Plus Lenacapavir Keep Control of HIV in People on Complex Regimens - Mark Mascolini (07/27/24)
- Dolutegravir-containing antiretroviral therapy and incident hypertension: findings from a prospective cohort in Kenya, Nigeria, Tanzania, and Uganda - (07/27/24)
-
Additional Time Post-Integrase Inhibitor to Protease Inhibitor Switch Shows Trend to Weight Loss: DEFINE 48-week Results - (07/27/24)
- Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASO-DOBLE (GeSIDA 11720) randomized clinical trial. - (07/27/24)
- Viral suppression, viral failure and safety outcomes in children and adolescents on dolutegravir (DTG) in Europe and Thailand - (07/27/24)
- Failure to achieve undetectable viral load caused by HIV expression from defective proviruses and large reservoir size - (07/27/24)
- Antimicrobial resistance (AMR) in Neisseria gonorrhoeae (GC)
infections among MSM on Doxycycline post-exposure prophylaxis. - (07/24/24)
- Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study - (07/24/24)
-
No Confirmed Virological Failures (CVF) for 144 Weeks When Switching 2-/3-/4-Drug ART to DTG/3TC in Heavily Treatment-Experienced PLWHA with Prior M184V/I and Multiple Virological Failures in the Prospective SOLAR-3D Study - (07/24/24)
|
|
| |
|
|
|
|
|
|
